Statement Of Comprehensive Income [Abstract]

Innate Pharma - Filing #5981200

Concept	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31
Statement of comprehensive income [abstract]
Profit (loss)	49 471 EUR	— EUR	— EUR	— EUR	—	— EUR	—	— EUR	49 471 EUR	— EUR	7 570 EUR	7 570 EUR	— EUR	—	— EUR	— EUR	— EUR	—	— EUR	— EUR
Other comprehensive income [abstract]
Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]
Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans	— EUR	— EUR	— EUR	— EUR	36,000 EUR	— EUR	—	— EUR	36,000 EUR	36,000 EUR	394,000 EUR	— EUR	— EUR	394,000 EUR	— EUR	— EUR	— EUR	—	— EUR	394,000 EUR
Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]
Exchange differences on translation [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations	— EUR	— EUR	— EUR	— EUR	—	— EUR	504,000 EUR	— EUR	504,000 EUR	504,000 EUR	276,000 EUR	— EUR	994,000 EUR	—	— EUR	— EUR	— EUR	718,000 EUR	— EUR	718,000 EUR
Other comprehensive income	—	—	—	—	—	—	—	—	468,000 EUR	—	670,000 EUR	—	—	—	—	—	—	—	—	—
Comprehensive income	49 471 EUR	— EUR	— EUR	— EUR	—	— EUR	—	— EUR	49 939 EUR	468,000 EUR	6 900 EUR	7 570 EUR	994,000 EUR	—	— EUR	— EUR	— EUR	—	— EUR	324,000 EUR